Structured obesity care pathway with lifestyle support and GLP-1 therapy in Algeria
Official title: OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
Run by University of Health Sciences, Algeria · NCT07779343 · Data updated 2026-11-12
This study tests whether a structured, multidisciplinary obesity program plus optional GLP-1 therapy helps adults with obesity in Algeria lose weight and improve health compared with usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of Health Sciences, Algeria Academic / other |
| Locations | 1 site (Algiers) |
| Status | Recruiting |
| Started | January 22, 2026 |
| Main results expected | January 23, 2028 |
| Study ends | January 23, 2028 |
| Registry record updated | August 21, 2026 |
| Trial ID | NCT07779343 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–65 with BMI ≥30 kg/m² who consent and can adhere to follow-up in Algerian healthcare facilities.
✕Probably not a fit
Patients unlikely to benefit include those unable to participate in follow-up, with recent unstable cardiovascular events, active malignancy, or contraindications to the planned therapies.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The OBESIAL study is a prospective pragmatic trial enrolling 300 adults with obesity in Algeria to compare structured multidisciplinary care against usual care over 18 months. The structured pathway includes coordinated medical follow-up, personalized nutrition, adapted physical activity, therapeutic education, and multidisciplinary support, with a nested comparison in the structured group between lifestyle plus GLP-1 receptor agonist therapy and lifestyle alone. The primary outcome is the share of participants achieving at least 5% weight loss at 18 months, with secondary outcomes spanning body composition, metabolism, treatment adherence, and obesity-related measures. Analyses will use mixed-effects models and multivariable approaches to identify factors associated with response. Results aim to inform optimization of structured obesity care pathways in Algeria and potentially other African healthcare settings.
Why it matters
Potential benefit: If successful, participants could achieve meaningful weight loss and better metabolic health through a coordinated care approach and, in some groups, GLP-1 therapy.
How similar studies have gone: Prior studies suggest structured multidisciplinary approaches with lifestyle support can improve weight-related outcomes, but this real-world, resource-limited setting with nested GLP-1 assessment is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18-65 years * BMI ≥30 kg/m² * Written informed consent obtained prior to enrolment Exclusion Criteria: * Refusal to participate or inability to adhere to follow-up procedures * Pregnancy at enrolment * Severe or unstable comorbidities compromising safety or participation, including: * Recent acute cardiovascular event (\<60 days) * Active malignancy * Severe unstable organic disease * Previous bariatric surgery * Obesity pharmacotherapy within the previous 90 days * Known contraindication to planned therapeutic options * Severe unstable psychiatric disorders * Genetic obesity or obesity secondary to uncontrolled endocrine disease Exclusion Criteria During Follow-up * Pregnancy occurring during follow-up * Initiation of chronic treatment associated with weight gain
Where it's running
-
Department of Medicine, , Mother and Child Hospital of the Army (MCHA), Algiers University Hospital, Algiers, Algeria.
Algiers, Algeria Recruiting
Study contacts
- Principal investigator: Mounira Chanegriha, Professor — University of health sciences, Faculty of Medicine, Algiers, Algeria
- Study coordinator: Mounira Professor Chanegriha. Head of Medicine department, Professor
- Email: m.chanegriha@univ-alger.dz
- Phone: +21321905656
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Real-Time Glucose Monitoring in Newly Diagnosed Type 2 Diabetes
This study tests whether real-time glucose monitoring helps people with newly diagnosed type 2 diabetes manage glucose better than traditional finger-prick testing.
-
AI-based prediction of difficult airway in bariatric patients
Aims to test whether artificial intelligence can better predict difficult airway in adults undergoing bariatric surgery than traditional preoperative tests.
-
Endoscopic sleeve plus pulsENDO in obese adults with type 2 diabetes
This trial tests whether combining Endoscopic Sleeve Gastro plasty (ESG) with pulsed electrical duodenal therapy (pulsENDO) is safe and helpful for adults with obesity and type 2 diabetes.
-
Automated Passive Case-Finding for Advanced Liver Fibrosis in MASLD
This program automatically screens high‑risk adults aged 50–75 in primary care to see if they have advanced liver fibrosis and possible MASLD, using routine blood tests and reflex lab tests without extra work for clinicians.
-
Hydration Support to Help GLP-1 Therapy Side Effects
This 17-week program tests whether boosting hydration in people starting GLP-1 receptor agonist therapy can lessen side effects and help people continue treatment.
-
Explainable AI helps families manage obesity in kids and young adults with diabetes or asthma
This study tests a family-centered digital program to help adolescents and young adults with overweight or obesity, including those with Type 1 diabetes or asthma, see if the program improves wellbeing and healthy habits over 3 months.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.